Psoriatic arthritis (PsA) is an inflammatory disorder characterized by diverse phenotypes extending beyond the joints, often linked with metabolic syndrome (MetS). MetS, marked by obesity, hypertension, hyperglycemia, and hyperlipidemia, has a higher prevalence in patients with PsA, likely due to persistent inflammation and elevated pro-inflammatory cytokines. The coexistence of PsA and MetS significantly elevates the risk of cardiovascular disease, impacting morbidity and mortality. Given this strong association, it’s crucial for healthcare providers to screen patients with PsA for MetS and manage their cardiometabolic risk factors, while also monitoring potential treatment-related adverse effects.

The relationship between PsA and MetS underscores the systemic nature of psoriatic disease, which not only affects the skin and joints but also influences cardiovascular health. The overlap of inflammatory pathways and genetic predispositions between PsA and MetS highlights the importance of understanding their interconnectedness. Treatment considerations for PsA should thus encompass the management of co-morbidities and lifestyle changes, like smoking cessation and weight loss, to mitigate cardiovascular events. Collaboration among healthcare professionals is key to early detection and optimal management of PsA patients with MetS.

Reference: Aljohani R. Metabolic Syndrome and Its Components in Psoriatic Arthritis. Open Access Rheumatol. 2022;14:7-16. doi: 10.2147/OARRR.S347797.